Denmark · Delayed Price · Currency is DKK Novozymes Earnings Call Transcripts
Fiscal Year 2025
-
Organic sales grew 7% in 2025, with strong volume-driven growth across all segments and a 37.1% adjusted EBITDA margin, despite currency headwinds. 2026 guidance targets 5%-7% organic growth and continued margin expansion, supported by innovation, synergies, and capacity investments.
-
Organic sales grew 8% in the first nine months, driven by strong volume growth, innovation, and emerging market performance. Adjusted EBITDA margin rose to 37.3% despite currency headwinds, and full-year guidance was raised to 7%-8% organic sales growth.
-
Organic sales grew 9% in H1 2025, with adjusted EBITDA margin up to 37.4% despite currency headwinds. 2025 guidance was narrowed to 6%-8% organic growth, and the 2030 strategy targets 6%-9% CAGR, ~39% EBITDA margin, and ~16% ROIC, supported by innovation and strong emerging market growth.
-
Q1 2025 saw 11% organic sales growth and a 38.3% adjusted EBITDA margin, driven by volume, pricing, and synergies. All segments delivered double-digit growth, with strong innovation and emerging market penetration. Full-year guidance for 5%-8% organic sales growth and 37%-38% EBITDA margin is maintained despite currency headwinds and macro uncertainty.
-
The meeting celebrated a successful first year post-merger, with strong financial growth, high integration progress, and robust innovation. All proposals, including dividend and board elections, were approved, and the company reaffirmed its commitment to sustainability and global leadership in biosolutions.
-
The acquisition secures full control of the animal biosolutions value chain, enabling direct market access, cross-selling, and innovation by integrating enzymes and probiotics. Financially, it is accretive to revenue, EBITDA, and EPS, with immediate and long-term growth synergies expected.
Fiscal Year 2024
-
Delivered 8% organic sales growth in 2024 with strong margin expansion and robust cash flow. 2025 guidance targets 5%-8% organic growth and 37%-38% adjusted EBITDA margin, supported by synergies, innovation, and continued investment, while managing risks from market exits and global uncertainties.
-
Energy segment growth is driven by diversification across markets, feedstocks, and geographies, with innovation and customer intimacy fueling performance improvements. Emerging opportunities in sustainable aviation fuel and enzyme-based biodiesel are supported by regulatory trends and global expansion. Market leadership is maintained through tailored solutions and close customer engagement.
-
Organic sales grew 9% in the first nine months, with strong Q3 acceleration and 29 new product launches. Full-year growth is now expected at the upper end of 7%-8%, with robust performance across all segments and continued synergy realization from integration.
-
Organic sales grew 7% in H1 2024, with strong Q2 momentum and improved margins. Full-year guidance was raised, driven by innovation, cost synergies, and robust segment performance, especially in emerging markets. Integration and cash flow remain strong.
-
The company is executing a focused strategy as a global biosolutions leader, reaffirming 6%-8% organic growth through 2025 and targeting accelerated growth beyond. Financial guidance is upgraded, with strong synergy realization, robust R&D, and operational excellence supporting margin expansion and innovation across human and planetary health markets.